Mar 21, 2024
In this episode, host Shikha Jain, MD, speaks
with Barnaby Balmforth, PhD, about the evolution
of genomics in cancer care, the impact of personalized care tools
and more.
• Welcome to another exciting episode of Oncology
Overdrive :58
• About Balmforth 1:12
• The interview 3:01
• How did you get to where you are today? What drove
you to become a leader in this space?
3:45
• What is genomics, and why is genomic analysis
important in cancer care? 7:18
• Jain and Balmforth on the evolution of technology
and challenges facing genomics and diagnostic testing to achieve
personalized care for individual patients.
11:59
• In addition to time, can you speak on the challenge
of access for this type of technology?
13:20
• How have you been able to implement “next day” test
results and reports of your technology?
17:50
• Jain and Balmforth on how Biofidelity’s technology
can transform the delivery of care, as well as its psychological
and mental impact. 19:06
• What’s coming down the line for you and Biofidelity?
20:56
• What are your thoughts for when you expand beyond
thoracic oncology? What are your long-term visions for other
disease sites? 24:19
• Do you have any thoughts on AI and how it may
influence genomics in cancer care?
25:51
• If someone could only listen to the last few minutes
of this episode, what would you want them to take away?
28:37
• How to contact Balmforth
30:37
• Thanks for listening
31:10
Barnaby Balmforth, PhD, is co-founder and CEO of
Biofidelity. Barnaby has more than 15 years’ experience in the
leadership of multidisciplinary technology development.
We’d love to hear from you! Send your comments/questions to Dr.
Jain at oncologyoverdrive@healio.com.
Follow Healio on X, formerly known as Twitter, and LinkedIn:
@HemOncToday and
https://www.linkedin.com/company/hemonctoday/.
Follow Dr. Jain on X, formerly known as Twitter:
@ShikhaJainMD. Balmforth can be reached via the Biofidelity website.
Disclosures: Jain reports no relevant financial
disclosures. Balmforth reports he is an employee of Biofidelity and
owns shares in the company.